Response to imatinib mesylate in patients with hypereosinophilic syndrome
International Journal of Hematology, 08/09/2012
Arefi M et al. – Using of low–dose imatinib mesylate (100 mg/day) a hematological and molecular remission in all patients displaying the FIP1L1–PDGFRA fusion gene was observed. Therefore, imatinib may be effective for use in the treatment of chronic eosinophilic leukemia, and patients should be treated before tissue damage.Methods
- The authors prospectively studied 78 patients with chronic eosinophilia.
- In all cases, the most salient clinical and biological characteristics as well as the response to the therapy were analyzed.
- In addition, they performed conventional cytogenetics and fluorescent in situ hybridization (FISH) with three BACs covering the FIP1-like-1 (FIP1L1)/platelet-derived growth factor receptor-α gene (PDGFRA) fusion.
- Nineteen of 78 patients (24 %) presented criteria of HES.
- The majority of patients were male (18) with median age of 49years (range 19–84years).
- FIP1L1–PDGFRA fusion was found in eight patients.
- Patients with FIP1L1–PDGFRA fusion presented with more bone marrow eosinophils and peripheral blood eosinophilia as well as anemia, leukocytosis and thrombocytopenia.
- Using of low-dose imatinib mesylate (100mg/day) a hematological and molecular remission in all patients displaying the FIP1L1–PDGFRA fusion gene was observed.